Parisa Takalloo
Internal Medicine · Washington, DCNPI 1437715562
Payments from drug & device makers
Across 102 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$648
- Lilly USA, LLC$311
- Boehringer Ingelheim$237
- Sanofi-aventis U.S. LLC$224
- Xeris Pharmaceuticals, Inc.$162
- Dexcom, Inc.$129
- plus $982 from 17 others
What the payments were for
- Food & beverage$2,694100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 24 | $648 |
| Lilly USA, LLC | 11 | $311 |
| Boehringer Ingelheim | 9 | $237 |
| Sanofi-aventis U.S. LLC | 8 | $224 |
| Xeris Pharmaceuticals, Inc. | 7 | $162 |
| Dexcom, Inc. | 4 | $129 |
| Cequr Corporation | 2 | $119 |
| Tolmar, Inc. | 4 | $113 |
| Madrigal Pharmaceuticals | 3 | $98 |
| Abbott | 4 | $97 |
| Medtronic | 3 | $78 |
| Recordati_rare_diseases_inc. | 4 | $76 |
| Insulet Corporation | 3 | $69 |
| Tandem Diabetes Care, Inc. | 3 | $64 |
| Soleno Therapeutics, Inc. | 2 | $54 |
| Novo Nordisk | 2 | $46 |
| AstraZeneca | 2 | $38 |
| Bayer | 2 | $35 |
| Averitas Pharma Inc. | 1 | $28 |
| Sequel Med Tech, LLC | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$2,694 in reported general payments places this provider in the 85th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 66 | $88,904 |
| OzempicSemaglutide | 23 | $23,959 |
| JardianceEmpagliflozin | 19 | $18,097 |
| JanuviaSitagliptin Phosphate | 11 | $14,922 |
| FarxigaDapagliflozin Propanediol | 13 | $11,132 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 43 | $3,264 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,781 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 25 | $1,394 |
| Ezetimibe | 16 | $233 |
| Metformin Hcl | 45 | $208 |
| Atorvastatin Calcium | 27 | $120 |
| Levothyroxine Sodium | 22 | $119 |
| Metformin Hcl ErMetformin Hcl | 17 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $311 | $88,90466 claims |
| Novo NordiskOzempic | $46 | $23,95923 claims |
| Boehringer IngelheimJardiance | $237 | $18,09719 claims |
| AstraZenecaFarxiga | $38 | $11,13213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Federico AschWashington$4.6M
- Geoffrey GibneyWashington$2.3M
- Nnemdi Kamanu EliasWashington$939K
- Andrea SingerWashington$930K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$454K
- Ida BergstromWashington$295K
- Miriam CameronWashington$290K
- Bruce RashbaumWashington$265K
- Kevin GriffithsWashington$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.